

# Catherine Sautes-fridman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8011926/publications.pdf>

Version: 2024-02-01

181  
papers

29,900  
citations

7561

77  
h-index

5677

162  
g-index

192  
all docs

192  
docs citations

192  
times ranked

33660  
citing authors

#	ARTICLE	IF	CITATIONS
1	The immune contexture in human tumours: impact on clinical outcome. <i>Nature Reviews Cancer</i> , 2012, 12, 298-306.	12.8	3,873
2	Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. <i>Genome Biology</i> , 2016, 17, 218.	3.8	1,980
3	The immune contexture in cancer prognosis and treatment. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 717-734.	12.5	1,590
4	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
5	B cells are associated with survival and immunotherapy response in sarcoma. <i>Nature</i> , 2020, 577, 556-560.	13.7	1,158
6	Immune infiltration in human tumors: a prognostic factor that should not be ignored. <i>Oncogene</i> , 2010, 29, 1093-1102.	2.6	942
7	Tertiary lymphoid structures in the era of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 307-325.	12.8	879
8	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019, 49, 1457-1973.	1.6	766
9	Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 832-844.	2.5	564
10	Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells. <i>Cancer Research</i> , 2014, 74, 705-715.	0.4	466
11	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 4057-4066.	3.2	433
12	Tertiary lymphoid structures in cancer and beyond. <i>Trends in Immunology</i> , 2014, 35, 571-580.	2.9	418
13	Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma. <i>Cancer Research</i> , 2011, 71, 5412-5422.	0.4	404
14	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
15	The clinical role of the TME in solid cancer. <i>British Journal of Cancer</i> , 2019, 120, 45-53.	2.9	380
16	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3031-3040.	3.2	355
17	Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates. <i>Cancer Research</i> , 2011, 71, 5601-5605.	0.4	341
18	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 784.	2.2	339

#	ARTICLE	IF	CITATIONS
19	A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. <i>Blood</i> , 2006, 107, 190-196.	0.6	335
20	The Structure of a Human Type III Fc $\gamma$ 3 Receptor in Complex with Fc. <i>Journal of Biological Chemistry</i> , 2001, 276, 16469-16477.	1.6	325
21	Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. <i>Blood</i> , 2002, 99, 2114-2121.	0.6	309
22	Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin. <i>Clinical Cancer Research</i> , 2013, 19, 4079-4091.	3.2	301
23	Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. <i>Immunological Reviews</i> , 2016, 271, 260-275.	2.8	277
24	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4416-4428.	3.2	252
25	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting. <i>Clinical Cancer Research</i> , 2015, 21, 1329-1339.	3.2	250
26	Characterization of Chemokines and Adhesion Molecules Associated with T cell Presence in Tertiary Lymphoid Structures in Human Lung Cancer. <i>Cancer Research</i> , 2011, 71, 6391-6399.	0.4	245
27	Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. <i>Frontiers in Immunology</i> , 2016, 7, 407.	2.2	238
28	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008866.	2.1	237
29	Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. <i>Cancer Research</i> , 1999, 59, 3698-704.	0.4	235
30	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmmunology</i> , 2014, 3, e957994.	2.1	223
31	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, 58-65.	1.8	219
32	Context-dependent roles of complement in cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 698-715.	12.8	217
33	Differential Modulation of Stimulatory and Inhibitory Fc $\gamma$ 3 Receptors on Human Monocytes by Th1 and Th2 Cytokines. <i>Journal of Immunology</i> , 2001, 166, 531-537.	0.4	215
34	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. <i>Immunity</i> , 2022, 55, 527-541.e5.	6.6	215
35	CD14 <sup>dim</sup> CD16 <sup>+</sup> and CD14 <sup>+</sup> CD16 <sup>+</sup> Monocytes in Obesity and During Weight Loss. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2322-2330.	1.1	210
36	The Non-Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 377-390.	2.5	204

#	ARTICLE	IF	CITATIONS
37	Trial watch. <i>Oncolimmunology</i> , 2012, 1, 1323-1343.	2.1	203
38	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. <i>Oncolimmunology</i> , 2012, 1, 894-907.	2.1	194
39	Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 1-24.	0.7	193
40	Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. <i>Journal of Clinical Investigation</i> , 2010, 120, 1285-1297.	3.9	191
41	Trial Watch. <i>Oncolimmunology</i> , 2012, 1, 699-739.	2.1	184
42	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 441-457.	12.5	176
43	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e24612.	2.1	175
44	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. <i>Nature Cancer</i> , 2021, 2, 794-802.	5.7	173
45	Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. <i>Cancer Research</i> , 2016, 76, 1746-1756.	0.4	164
46	Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. <i>Kidney International</i> , 2010, 77, 339-349.	2.6	163
47	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016, 130, 95-190.	1.1	160
48	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. <i>Cancer Immunology Research</i> , 2019, 7, 1091-1105.	1.6	153
49	Trial watch. <i>Oncolimmunology</i> , 2012, 1, 1111-1134.	2.1	152
50	The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. <i>Journal of Medical Genetics</i> , 2009, 46, 447-450.	1.5	142
51	Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. <i>Blood</i> , 2009, 114, 2837-2845.	0.6	140
52	Alternative complement pathway assessment in patients with atypical HUS. <i>Journal of Immunological Methods</i> , 2011, 365, 8-26.	0.6	140
53	The immune contexture of primary and metastatic human tumours. <i>Current Opinion in Immunology</i> , 2014, 27, 8-15.	2.4	137
54	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e27878.	2.1	134

#	ARTICLE	IF	CITATIONS
55	Trial Watch. <i>Oncolimmunology</i> , 2013, 2, e25238.	2.1	132
56	Cancer immune contexture and immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 39, 7-13.	2.4	132
57	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. , 2018, 6, 139.		131
58	Jejunal T Cell Inflammation in Human Obesity Correlates with Decreased Enterocyte Insulin Signaling. <i>Cell Metabolism</i> , 2015, 22, 113-124.	7.2	130
59	A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. <i>Blood</i> , 2012, 119, 4182-4191.	0.6	128
60	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. <i>Cell Reports</i> , 2012, 2, 257-269.	2.9	122
61	The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact. <i>Cancer Microenvironment</i> , 2013, 6, 117-122.	3.1	119
62	Trial watch. <i>Oncolimmunology</i> , 2012, 1, 1557-1576.	2.1	110
63	Trial watch. <i>Oncolimmunology</i> , 2012, 1, 179-188.	2.1	104
64	Trial Watch: Monoclonal antibodies in cancer therapy. <i>Oncolimmunology</i> , 2012, 1, 28-37.	2.1	103
65	Characteristics of tertiary lymphoid structures in primary cancers. <i>Oncolimmunology</i> , 2013, 2, e26836.	2.1	103
66	Trial Watch. <i>Oncolimmunology</i> , 2013, 2, e26621.	2.1	101
67	Crystal Structure of the Extracellular Domain of a Human Fc $\gamma$ RIII. <i>Immunity</i> , 2000, 13, 387-395.	6.6	98
68	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolimmunology</i> , 2015, 4, e974411.	2.1	97
69	Overall Neutralization of Complement Factor H by Autoantibodies in the Acute Phase of the Autoimmune Form of Atypical Hemolytic Uremic Syndrome. <i>Journal of Immunology</i> , 2012, 189, 3528-3537.	0.4	96
70	Tumor microenvironment is multifaceted. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 13-25.	2.7	95
71	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e22789.	2.1	92
72	Profiling of the Three Circulating Monocyte Subpopulations in Human Obesity. <i>Journal of Immunology</i> , 2015, 194, 3917-3923.	0.4	92

#	ARTICLE	IF	CITATIONS
73	B cells and cancer: To B or not to B?. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	91
74	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 981-988.	2.0	89
75	Trial Watch. Oncolytic viruses and cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1117740.	2.1	88
76	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. <i>Nature Medicine</i> , 2022, 28, 1199-1206.	15.2	88
77	Trial Watch. <i>Oncolmmunology</i> , 2013, 2, e25595.	2.1	83
78	TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2014, 74, 5008-5018.	0.4	83
79	Fc $\gamma$ 3 receptors. <i>Immunology Letters</i> , 2004, 92, 199-205.	1.1	82
80	PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 192-196.	1.6	81
81	Dendritic cells in the tumor microenvironment: prognostic and theranostic impact. <i>Seminars in Immunology</i> , 2020, 48, 101410.	2.7	81
82	The New Histologic Classification of Lung Primary Adenocarcinoma Subtypes Is a Reliable Prognostic Marker and Identifies Tumors With Different Mutation Status. <i>Chest</i> , 2014, 146, 633-643.	0.4	80
83	Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. <i>Blood</i> , 2002, 100, 3646-3655.	0.6	78
84	Structural basis of the interaction between IgG and Fc $\gamma$ 3 receptors. <i>Journal of Molecular Biology</i> , 2000, 295, 213-224.	2.0	76
85	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e29179.	2.1	76
86	TRAF4 overexpression is a common characteristic of human carcinomas. <i>Oncogene</i> , 2007, 26, 142-147.	2.6	72
87	Trial Watch. <i>Oncolmmunology</i> , 2012, 1, 306-315.	2.1	70
88	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27048.	2.1	69
89	Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. <i>Journal of Autoimmunity</i> , 2011, 36, 9-15.	3.0	67
90	Nivolumab, nivolumab+ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 612-624.	5.1	66

#	ARTICLE	IF	CITATIONS
91	Measles virus nucleoprotein induces cell-proliferation arrest and apoptosis through NTA1 and NCOR1/FcγRIIB1 interactions, respectively. <i>Journal of General Virology</i> , 2005, 86, 1771-1784.	1.3	65
92	The Immune Microenvironment: A Major Player in Human Cancers. <i>International Archives of Allergy and Immunology</i> , 2014, 164, 13-26.	0.9	63
93	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. <i>Genome Medicine</i> , 2020, 12, 86.	3.6	63
94	Association of FcγRII with Low-Density Detergent-Resistant Membranes Is Important for Cross-Linking-Dependent Initiation of the Tyrosine Phosphorylation Pathway and Superoxide Generation. <i>Journal of Immunology</i> , 2001, 167, 5814-5823.	0.4	61
95	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7351-7362.	3.2	61
96	Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies. <i>Advances in Hematology</i> , 2012, 2012, 1-13.	0.6	60
97	M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. , 2020, 8, e000979.		60
98	Association of IL-36β with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 109-120.	2.0	59
99	Complement System: Promoter or Suppressor of Cancer Progression?. <i>Antibodies</i> , 2020, 9, 57.	1.2	58
100	Lung Tumor Microenvironment Induces Specific Gene Expression Signature in Intratumoral NK Cells. <i>Frontiers in Immunology</i> , 2013, 4, 19.	2.2	56
101	Cytokine Profile in Human Eyes: Contribution of a New Cytokine Combination for Differential Diagnosis between Intraocular Lymphoma or Uveitis. <i>PLoS ONE</i> , 2013, 8, e52385.	1.1	55
102	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). <i>Oncotmunology</i> , 2015, 4, e1049804.	2.1	51
103	The immune response in cancer: from immunology to pathology to immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 127-135.	1.4	51
104	Therapeutic Targeting of the Colorectal Tumor Stroma. <i>Gastroenterology</i> , 2020, 158, 303-321.	0.6	51
105	C1q+ macrophages: passengers or drivers of cancer progression. <i>Trends in Cancer</i> , 2022, 8, 517-526.	3.8	51
106	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. <i>Frontiers in Oncology</i> , 2018, 8, 390.	1.3	46
107	Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. <i>Seminars in Immunology</i> , 2020, 48, 101406.	2.7	44
108	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. <i>Clinical Cancer Research</i> , 2020, 26, 4381-4389.	3.2	44

#	ARTICLE	IF	CITATIONS
109	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. <i>Cancer Immunology Research</i> , 2021, 9, 891-908.	1.6	43
110	Regulation of production of soluble Fc $\gamma$ 3 receptors type III in normal and pathological conditions. <i>Immunology Letters</i> , 1999, 68, 125-134.	1.1	41
111	Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. <i>Cancer Immunology Research</i> , 2021, 9, 909-925.	1.6	40
112	Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2021, 27, 6749-6760.	3.2	39
113	Tumor microenvironment in NSCLC suppresses NK cells function. <i>Oncot Immunology</i> , 2012, 1, 244-246.	2.1	34
114	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e981-e994.	0.9	34
115	FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer. <i>British Journal of Cancer</i> , 2012, 106, 1989-1996.	2.9	33
116	Preclinical Study of Ublituximab, a Glycoengineered Anti-Human CD20 Antibody, in Murine Models of Primary Cerebral and Intraocular B-Cell Lymphomas. , 2013, 54, 3657.		33
117	Soluble CD16 Inhibits CR3 (CD11b/CD18)-Mediated Infection of Monocytes/Macrophages by Opsonized Primary R5 HIV-1. <i>Journal of Immunology</i> , 2001, 166, 3377-3383.	0.4	32
118	Mannose Receptor Ligand-Positive Cells Express the Metalloprotease Decysin in the B Cell Follicle. <i>Journal of Immunology</i> , 2001, 167, 5052-5060.	0.4	31
119	Impaired Th1/Tc1 Cytokine Production of Tumor-Infiltrating Lymphocytes in a Model of Primary Intraocular B-Cell Lymphoma. , 2007, 48, 3223.		31
120	Selective expression of inhibitory Fc $\gamma$ 3 receptor by metastatic melanoma impairs tumor susceptibility to IgG $\alpha$ -dependent cellular response. <i>International Journal of Cancer</i> , 2008, 123, 2832-2839.	2.3	31
121	Hereditary complement C7 deficiency in nine families: Subtotal C7 deficiency revisited. <i>European Journal of Immunology</i> , 2007, 37, 1377-1385.	1.6	30
122	Shaping of an effective immune microenvironment to and by cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 991-997.	2.0	30
123	Revisiting immune escape in colorectal cancer in the era of immunotherapy. <i>British Journal of Cancer</i> , 2019, 120, 815-818.	2.9	30
124	Immune-based identification of cancer patients at high risk of progression. <i>Current Opinion in Immunology</i> , 2018, 51, 97-102.	2.4	29
125	Modulation of tumor growth by inhibitory Fc $\gamma$ 3 receptor expressed by human melanoma cells. <i>Journal of Clinical Investigation</i> , 2002, 110, 1549-1557.	3.9	29
126	Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2008, 30, 238-245.	3.0	28



#	ARTICLE	IF	CITATIONS
127	Control of tumor development by intratumoral cytokines. <i>Immunology Letters</i> , 1999, 68, 135-139.	1.1	27
128	Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses. <i>Oncolimmunology</i> , 2014, 3, e28976.	2.1	26
129	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Oncolimmunology</i> , 2015, 4, e1026531.	2.1	26
130	LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial. <i>Annals of Oncology</i> , 2020, 31, S1157.	0.6	26
131	Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 643065.	1.3	26
132	Fc $\gamma$ RIIB is differentially expressed during B cell maturation and in B-cell lymphomas. <i>British Journal of Haematology</i> , 2004, 124, 55-62.	1.2	25
133	Characterization of immune functions in TRAF4-deficient mice. <i>Immunology</i> , 2008, 124, 562-574.	2.0	25
134	TLS in Tumors: What Lies Within. <i>Trends in Immunology</i> , 2016, 37, 1-2.	2.9	24
135	N-glycosylation profile of recombinant human soluble Fc $\gamma$ receptor III. <i>Glycobiology</i> , 2002, 12, 507-515.	1.3	22
136	Th17 Cells Are Involved in the Local Control of Tumor Progression in Primary Intraocular Lymphoma. <i>PLoS ONE</i> , 2011, 6, e24622.	1.1	21
137	Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	21
138	Site-specific N-glycosylation analysis of soluble Fc $\gamma$ receptor IIIb in human serum. <i>Scientific Reports</i> , 2018, 8, 2719.	1.6	21
139	Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics. <i>Clinical and Experimental Immunology</i> , 2011, 165, 329-337.	1.1	17
140	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 463-474.	1.4	16
141	Fc gamma receptors and cancer. <i>Seminars in Immunopathology</i> , 2006, 28, 321-328.	4.0	15
142	Metastatic Melanomas Express Inhibitory Low Affinity Fc Gamma Receptor and Escape Humoral Immunity. <i>Dermatology Research and Practice</i> , 2010, 2010, 1-11.	0.3	15
143	PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 11507-11507.	0.8	15
144	Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. <i>Frontiers in Immunology</i> , 2012, 3, 98.	2.2	14

#	ARTICLE	IF	CITATIONS
145	Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2022, 27, 501-511.	1.9	14
146	Activation of Human Peripheral IgM+ B Cells Is Transiently Inhibited by BCR-Independent Aggregation of Fc $\gamma$ RIIB. <i>Journal of Immunology</i> , 2008, 181, 5350-5359.	0.4	13
147	Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 18.	3.5	13
148	Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. , 2022, 10, e004885.		13
149	Modulation of tumor growth by inhibitory Fc $\gamma$ 3 receptor expressed by human melanoma cells. <i>Journal of Clinical Investigation</i> , 2002, 110, 1549-1557.	3.9	12
150	Presentation of Antigen in Immune Complexes Is Boosted by Soluble Bacterial Immunoglobulin Binding Proteins. <i>Journal of Experimental Medicine</i> , 1999, 189, 1217-1228.	4.2	11
151	Fc $\gamma$ RIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). <i>Leukemia</i> , 2004, 18, 2038-2040.	3.3	11
152	Expression of low-affinity Fc gamma receptor by a human metastatic melanoma line. <i>Immunology Letters</i> , 2000, 75, 1-8.	1.1	10
153	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. <i>Frontiers in Immunology</i> , 2011, 2, 66.	2.2	9
154	B cells and complement at the forefront of chemotherapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 393-394.	12.5	9
155	EFISâ€œ supported events: Courses, Schools, Symposia and Meetings with a European flavour. <i>European Journal of Immunology</i> , 2011, 41, 2467-2469.	1.6	8
156	50 <sup>th</sup> Anniversary of the French Society for Immunology (SFI). <i>European Journal of Immunology</i> , 2016, 46, 1545-1547.	1.6	8
157	Animal Models of Intraocular Lymphomas. <i>Ophthalmic Research</i> , 2008, 40, 208-211.	1.0	7
158	7000 Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N). <i>Annals of Oncology</i> , 2020, 31, S553.	0.6	7
159	Inhibition of Human Immunodeficiency Virus Transmission to CD4+T Cells after Gene Transfer of Constitutively Expressed Interferon $\gamma$ to Dendritic Cells. <i>Human Gene Therapy</i> , 2000, 11, 1695-1703.	1.4	5
160	EFIS: Driving women's representation in immunology in Europe. <i>European Journal of Immunology</i> , 2014, 44, 615-616.	1.6	5
161	Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies. <i>Journal of Neuro-Oncology</i> , 2015, 121, 9-18.	1.4	5
162	Complement Detection in Human Tumors by Immunohistochemistry and Immunofluorescence. <i>Methods in Molecular Biology</i> , 2021, 2227, 191-203.	0.4	5

#	ARTICLE	IF	CITATIONS
163	NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N). <i>Annals of Oncology</i> , 2019, 30, v360-v361.	0.6	4
164	Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death. <i>Methods in Enzymology</i> , 2020, 632, 15-25.	0.4	3
165	The immune microenvironments of lung and intraocular tumors. <i>Bulletin Du Cancer</i> , 2011, 98, E58-E61.	0.6	2
166	The 2011 Nobel Prize in Physiology or Medicine: Honor, sadness and lessons. <i>European Journal of Immunology</i> , 2011, 41, 3393-3393.	1.6	2
167	Tumor Immunology, toward a Success Story?. <i>Frontiers in Immunology</i> , 2015, 6, 65.	2.2	2
168	The Human Tumor Microenvironment. , 2018, , 5-21.		2
169	Editorial: Tertiary Lymphoid Structures: From Basic Biology to Translational Impact in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 870862.	2.2	2
170	EFISâ€”Ruggero Ceppellini Advanced Immunology School Course: Tumour immunology 2017: From tissue microenvironment to immunotherapy. Naples 16â€”18 October 2017. <i>European Journal of Immunology</i> , 2018, 48, 559-561.	1.6	1
171	Primary Central Nervous System Lymphomas (PCNSL) Are Distinct from Systemic DLBCL for Expression Pattern of Germinal Center and Activation B-Cell Markers. A GOELAMS Study.. <i>Blood</i> , 2004, 104, 2264-2264.	0.6	1
172	Immuno-molecular characterization of colorectal cancer tumors and its clinical implications. <i>Translational Cancer Research</i> , 2016, 5, S368-S370.	0.4	1
173	Super C3-convertases, formed by gain-of-function factor B or C3 mutant proteins are associated with atypical haemolytic uraemic syndrome with a poor outcome. <i>Molecular Immunology</i> , 2008, 45, 4098-4099.	1.0	0
174	The European Academy of Tumor Immunology: Bridging fields, continents and generations. <i>Oncolimmunology</i> , 2012, 1, 127-128.	2.1	0
175	Intratumoral classical complement pathway promotes tumor growth in renal cancer. <i>Molecular Immunology</i> , 2018, 102, 205.	1.0	0
176	NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma. <i>Annals of Oncology</i> , 2019, 30, v400-v401.	0.6	0
177	Abstract IA20: Cancer subtypes and their immune microenvironments. , 2016, , .		0
178	Abstract A085: Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary clear cell renal cell cancer. , 2016, , .		0
179	Abstract LB-273: Identity card of tumor-infiltrating regulatory T cells in the context of tertiary lymphoid structures in lung cancer patients. , 2016, , .		0
180	Abstract IA10: Tumor microenvironments: Prognostic and theranostic impacts. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
181	Les structures lymphoïdes tertiaires gèrent et propagent des plasmocytes produisant des anticorps antitumoraux dans le cancer du rein. <i>Medecine/Sciences</i> , 2022, 38, 536-538.	0.0	0